Takeda Pharmaceutical
313 hedge funds and large institutions have $1.98B invested in Takeda Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 83 increasing their positions, 98 reducing their positions, and 46 closing their positions.
13% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 46
4% more capital invested
Capital invested by funds: $1.9B → $1.98B (+$79.2M)
1% more funds holding
Funds holding: 311 → 313 (+2)
0.08% more ownership
Funds ownership: 6.82% → 6.9% (+0.08%)
10% less call options, than puts
Call options by funds: $54.6M | Put options by funds: $60.5M
15% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 98
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$131M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$21.5M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$14.6M |
| 4 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$13.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$43.4M |
| 2 |
GCM
Glenview Capital Management
New York
|
-$26.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$22.3M |
| 4 |
Citigroup
New York
|
-$16.9M |
| 5 |
AC
Adelphi Capital
London,
United Kingdom
|
-$12.1M |
TAK Hedge Fund Activity: Q4 2020 in Review
313 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2020, worth a combined $1.98B — up 4.2% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new TAK positions and 46 closed out — a net gain of 6 holders — while 83 added to existing stakes and 98 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $131M. The largest seller was LMR Partners, exiting entirely with an estimated $43.4M sold.
- 313 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2020, up from 311 in Q3 2020.
- Funds reported $1.98B of Takeda Pharmaceutical stock for Q4 2020, up 4.2% quarter-over-quarter.
- 52 funds opened new Takeda Pharmaceutical positions in Q4 2020 and 46 closed out, a net change of +6 holders.
- The largest Takeda Pharmaceutical buyer in Q4 2020 was ARK Investment Management, an estimated $131M added.
- The largest Takeda Pharmaceutical seller in Q4 2020 was LMR Partners, an estimated $43.4M sold.
Based on aggregated 13F filings for Q4 2020.